[An evaluation of the therapeutic activity and tolerance of ST-679 in patients with osteoarthritis at different sites. A controlled double-blind study vs tolmetin].
A multicentered study was carried out, under double-blind conditions, on 160 elderly patients afflicted with differently localized symptomatic osteoarthritis, for the purpose of evaluating the therapeutical efficacy and tolerability of ST-679 (per-os at a dose of 1200 mg pro die in 80 patients) and to compare them with those of tolmetin (per os at a dose of 1200 mg pro die in 80 patients). It was demonstrated that ST-679 was significantly active on all of the clinical parameters of the illness already recorded after a month of treatment. ST-679 was always excellently tolerated as shown by the scarce incidence of adverse reactions. Results of laboratory tests, of tests for hidden blood in the feces and of a gastroduodenoscopy confirmed the excellent biological and gastric tolerability of ST-679. ST-679 demonstrated, moreover, a significantly better tolerability with respect to tolmetin.
Lingetti
M
M
Divisione di Geriatria, USL 4, Presidio Ospedaliero, Regione Campania, Avellino.
Ciarimboli
M
M
Porfido
F A
FA
Imparato
L
L
Sorrentino
G P
GP
Garzya
G
G
Saraceni
G
G
Donati
G
G
Nolfe
G
G
D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D004347:Drug Interactions; D004361:Drug Tolerance; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology; D011758:Pyrroles / Q000627:therapeutic use*; D013997:Time Factors; D014046:Tolmetin / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011758:Pyrroles; C065762:ST 679; D014046:Tolmetin; D005998:Glycine
Valutazione dell'attività terapeutica e della tollerabilità di ST-679 in pazienti affetti da osteoartrite a diversa localizzazione. Studio doppio cieco controllato vs tolmetina.